Ipsen pays Day One $111M upfront for ex-US rights to pediatric brain tumor drug

Reynald Castañeda

Deputy Editor

In another move to boost its oncology portfolio, Ipsen is handing Day One Biopharmaceuticals $111 million upfront so it can take the pediatric brain tumor …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ipsen pays Day One $111M upfront for ex-US rights to pediatric brain tumor drug

Reynald Castañeda

Deputy Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Ipsen pays Day One $111M up­front for ex-US rights to pe­di­atric brain tu­mor drug

Deputy Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Ipsen pays Day One $111M upfront for ex-US rights to pediatric brain tumor drug